This article explores current clinical recommendations, surgical considerations, and safety factors to help patients and healthcare professionals determine the optimal timing for resuming GLP-1 therapy following surgical procedures
Based on a recent third-party analysis conducted by the actuarial firm Accorded, Noom Med is expected to drive 4.1x ROI versus the most common alternative for employers who wish to cover GLP-1s for their workforce
They work by slowing digestion, reducing appetite, and helping regulate blood sugar levels
To improve outcome observability, we restricted the analysis to patients receiving usual care within a Truveta health care system in the prior year, defined as an interaction in both consecutive 6-month periods in the year before GLP-1 RA initiation
(2016.) Behavioral Weight Loss for the Management of Menopausal Hot Flashes: A Pilot Study Khan, Saira J., et al